Will The Dark Tunnel For Korean Biopharmas End In 2023?
Eyes On Lung Cancer, Alzheimer’s Segment
Scrip wraps up major R&D and corporate developments for Korean biopharmas in 2022 and outlines what lies ahead for them in the new year.
Scrip wraps up major R&D and corporate developments for Korean biopharmas in 2022 and outlines what lies ahead for them in the new year.